+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06367283

Randomized Phase 3 Trial of Metformin for Treating Hand Osteoarthritis Symptoms Compared to Placebo

Led by Marius Henriksen · Updated on 2025-02-27

150

Participants Needed

1

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of metformin as a potential treatment for hand osteoarthritis symptoms. This randomized, placebo-controlled Phase 3 trial aims to compare metformin, given at up to 2 grams daily for 16 weeks, with a placebo to assess its impact on finger pain and other hand osteoarthritis symptoms. The study is led by Marius Henriksen and focuses on adults aged 18 years and older who have hand osteoarthritis with moderate finger pain. Participants receive metformin starting at 500 mg once daily with breakfast, with the dose increasing by 500 mg each week until reaching 2 grams per day or the maximum tolerated dose, divided into two doses with meals. The treatment period, including dose escalation, lasts 16 weeks. The placebo group receives tablets identical to metformin but without the active drug. Both groups are monitored throughout the study period. During the trial, participants will be assessed for finger pain, hand function, thumb base pain, hand pain overall, tender joint counts, patient global assessment, quality of life via the EQ-5D scale, hand strength, and treatment response after 16 weeks. Safety and eligibility will be carefully monitored through clinical evaluations and blood tests. The total involvement spans the 16-week treatment period, during which participants will attend scheduled visits for these evaluations.

CONDITIONS

Brief Title

Metformin Treatment of Patients with Hand Osteoarthritis

Research Team

K

Kasper Staberg Madsen

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here